Novel and selective ccr2 antagonists

A compound according to formula (I),

• wherein R3 is —C5-C6-heterocyclyl, wherein this —C5-C6-heterocyclyl denotes a 5 or 6 membered, saturated or unsaturated heterocyclic ring in that the 5 or 6 atoms of the ring system could be carbon atom or heteroatom, and wherein one, or two of the 5 or 6 atoms are heteroatoms, selected from among oxygen, and nitrogen, optionally being substituted by one or more groups selected from among —OH, —NH2, —C1-C6-alkyl, —O—C1-C6-alkyl, —CN, —CF3, —OCF3, halogen, —C(O)—CH3, and ═O;
• or wherein R3 denotes a group selected from among —CH2F, —CHF2, and —CF3;
• wherein A is a group selected from among
• wherein R7 is selected from among —H, —C1-C4-alkyl, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3, and wherein R8 is selected from among —H, —C1-C4-alkyl, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3,
• wherein Q is selected from among CH2 and O, and wherein R9 is selected from among —H, —C1-C4-alkyl, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3,
• and wherein R10 is selected from among —H, —C1-C4-alkyl, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3,
• wherein R11 is selected from among —H, —C1-C4-alkyl, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3, and wherein R12 is a ring selected from among —C3-C8-cycloalkyl, —C3-C8-heterocyclyl, —C5-C10-aryl, and —C5-C10-heteroaryl,
• wherein the ring R12 is optionally substituted with one or more groups selected from among —CF3, —O—CF3, —CN, —C1-C6-alkyl, —S—C1-C3-alkyl, and -halogen;
• R6 is a group of the structure -L1-R13,
• wherein L1 is selected from among —NH—, and —N(C1-C4-alkyl)-,
• and wherein R13 is selected from among —C5-C6-heterocyclyl comprising 1 or 2 hetero atoms selected from among N, and O,
• and wherein R13 is optionally substituted by one or more groups selected from among among —CF3, —OCF3, —CN, —OH, —O—C1-C4-alkyl, —C1-C6-alkyl, and -halogen;
• or R6 is a group of the structure —N(R1,R1′),
• wherein R1 and R1′, together form a —C2-C6-alkylene group such that a ring is formed, wherein one carbon atom may be replaced by a group selected from among NH, and O,
• and wherein such ring is optionally substituted with one or more groups selected from among —OH, —OCH3, —CF3, —OCF3, —CN, -halogen, —C1-C4-alkyl, ═O, and —N(C0-C3-alkyl)-SO2—C1-C3-alkyl;
• R2 is selected from among —H, -halogen, —CN, —O—C1-C4-alkyl, —C1-C4-alkyl, —CH═CH2, —C≡CH, -cyclopropyl, —CF3, —OCF3, —OCF2H, and —OCFH2;
• R4 is selected from among —H, —C1-C4-alkyl, —OH, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3;
• R5 is selected from among —H, —C1-C4-alkyl, —OH, —O—C1-C4-alkyl, -halogen, —CN, —CF3, and —OCF3;
• G and E are independently selected from among C—H or N;
• and
• n is 1, 2 or 3;
• or an acid addition salt with a pharmacologically acceptable acid.